{
  "issued_date": "2013-03-20", 
  "original_url": "http://www.mhra.gov.uk/Publications/Safetywarnings/DrugAlerts/CON251950", 
  "doc_details": {
    "Type": "Drug Alert", 
    "Series No": "EL (13)A/10", 
    "Audience": "Healthcare professionals", 
    "Published": "20 March 2013", 
    "Format": "Electronic only", 
    "Size": "A4", 
    "Pages": "1", 
    "Price": "Free", 
    "ISBN/ISSN": "", 
    "Author": "", 
    "Copyright": "Crown"
  }, 
  "_assets": [
    {
      "content_type": "application/pdf", 
      "title": " Class 4 Drug Alert (Caution in Use): Circadin 2mg prolonged-release tablets - Melatonin - RAD Neurim Pharmaceuticals EEC Limited - EL (13)A/10 (157Kb)", 
      "assetid": 0, 
      "original_url": "http://www.mhra.gov.uk/home/groups/is-md/documents/websiteresources/con251952.pdf", 
      "filename": "downloads/aafe4f14d37618e3bad61a1fd04bc40996c958bb/con251952.pdf", 
      "original_filename": "con251952.pdf"
    }
  ], 
  "body": "## DRUG ALERT\n\nCLASS 4 MEDICINES DEFECT INFORMATION\n\nCaution in Use\n\n  \n\n\nDistribute to Pharmacy Level  \n  \n20 March 2013  |   |  EL (13)A/10  |   |  Our ref:\u00a0 MDR 35-03/13   | \n\n* * *\n\nDear Healthcare Professional,\n\nRAD Neurim Pharmaceuticals EEC Limited\n\nCircadin 2mg prolonged-release tablets\n\n(Melatonin)\n\nEU/1/07/392/003\n\nFlynn Pharma Limited, distributors of Circadin 2mg prolonged-release tablets, has informed us that there is an error in the patient information leaflet (PIL) supplied in batches of this product distributed since 11 February 2013.\n\nThe error concerns the dosage instructions given under heading three, \u2018How to take Circadin\u2019, which state \u2018The recommended dose is one Circadin tablet (2mg) taken daily by mouth after food, 12 hours before bedtime.\u2019 The instructions should state \u2018The recommended dose is one Circadin tablet (2mg) taken daily by mouth after food, 1-2 hours before bedtime.\u2019 The SPC is correct and an updated version of the PIL is presented on the Electronic Medicines Compendium. Health Care Professionals are asked to ensure that patients are made aware of the correct dosage instructions.\n\nIn order to avoid stock disruption, affected stock is not being recalled. We understand that distribution of affected stock will cease as soon as stock containing the corrected PIL is available.\n\nRecipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter. Primary care trusts are asked to forward this to relevant clinics and to general practitioners and community pharmacists for information.\n\nYours faithfully\n\nAlison Bunce  \nPharmaceutical Assessor, DMRC\n\nMHRA Distribution (further recipients by cascade):  Regional Contacts for NHS Trusts and provider units  \nChief Pharmacists: England, Scotland, Wales, Northern Ireland  \nPrison Health Policy Unit (DH)  \nChief Pharmacists: \u00a0Jersey, Guernsey, Alderney, Sark, Isle of Man, Gibraltar  \nSpecial Hospitals  \nHealthcare Commission for distribution to independent health care establishments  \nPrimary care trusts (England) \n\n### Download documents:  \n  \n  * [ASSET_TAG](#ASSET0)\n", 
  "raw_html": "<div class=\"inner\">          \r\n\t\t\t\t<a name=\"main\"></a>\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"title\">\r\n\t\t\t\t\t<h2>DRUG ALERT</h2>\r\n\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element14)-->\r\n\t\t\t\t\t<p>CLASS 4 MEDICINES DEFECT INFORMATION</p>\r\n\t\t\t\t\t<!--SS_END_ELEMENT(region1_element14)-->\r\n\t\t\t\t</div>\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"drugalertdetails\">\r\n\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element15)-->\r\n\t\t\t\t\t<p>Caution in Use</p>\r\n\t\t\t\t\t<!--SS_END_ELEMENT(region1_element15)-->\r\n\t\t\t\t\t<br>\r\n\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element16)-->\r\n\t\t\t\t\t<p>Distribute to Pharmacy Level</p>\r\n\t\t\t\t\t<!--SS_END_ELEMENT(region1_element16)-->\r\n\t\t\t\r\n\t\t\t\t\t<table id=\"dateref\">\r\n\t\t\t\t\t\t<tr>\r\n\t\t\t\t\t\t\t<td align=\"left\">\r\n\t\t\t\t\t\t\t\r\n\r\n\t\t\t\t\t\t\t20 March 2013\r\n\t\t\t\t\t\t\t</td>\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t<td>\r\n\t\t\t\t\t\t\tEL (13)A/10\r\n\t\t\t\t\t\t\t</td>\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t<td align=\"right\">\r\n\t\t\t\t\t\t\t\tOur ref:&#160;\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element17)-->\r\n\t\t\t\t\t\t\t\t MDR 35-03/13 \r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element17)-->\r\n\t\t\t\t\t\t\t</td>\r\n\t\t\t\t\t\t</tr>\r\n\t\t\t\t\t</table>\r\n\t\t\t\t</div>\r\n\t\t\t\t<hr>\t\t\t\t\r\n          \t\t<!--SS_BEGIN_ELEMENT(region1_element12)-->\r\n          \t\t<!--SS_END_ELEMENT(region1_element12)--> \r\n          \t\t\r\n          \t\t \r\n          \t\t\r\n          \t\t<p>Dear Healthcare Professional,</p>\r\n\r\n\t\t\t\t<div class=\"druginfo\">\r\n\t\t\t\t\t<div class=\"left\">\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t<p>\r\n\t\t\t\t\t\t\t<span>RAD Neurim Pharmaceuticals EEC Limited</span>\r\n\t\t\t\t\t\t</p>\r\n\t\t\t\t\t\t\t\t\t\t\r\n          \t\t          \t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t<p>\r\n\t\t\t\t\t\t\t<span>Circadin 2mg prolonged-release tablets</span>\r\n\t\t\t\t\t\t</p>\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t<p>\r\n\t\t\t\t\t\t\t<span>(Melatonin)</span>\r\n\t\t\t\t\t\t</p>\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t</div>\r\n\t\t\t\t\t\r\n\t\t\t\t\t<div class=\"right\">\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t<span>EU/1/07/392/003</span>\r\n\t\t\t\t\t\t\r\n\t\t\t\t\t</div>\t\r\n\t\t\t\t</div>\t\t\t\t\r\n          \t\t\r\n\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment8,navigation_controls)-->\r\n\t\t\t\t<!-- only show the publication navigation controls if there is more than one page to the publication -->\r\n\t\t\t\r\n\t\t\t\t<!-- SS_END_SNIPPET(fragment8,navigation_controls)-->\r\n \t\t\r\n\t\t\t\t<!-- SS_BEGIN_SNIPPET(region1_element2,paged_publication)-->\r\n        \t\t<!-- <br>SS_DATAFILE: CON251950 -->\r\n\r\n<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<p></p><p>Flynn Pharma Limited, distributors of Circadin 2mg prolonged-release tablets, has informed us that there is an error in the patient information leaflet (PIL) supplied in batches of this product distributed since 11 February 2013.</p>\n\n<p>The error concerns the dosage instructions given under heading three, &#8216;How to take Circadin&#8217;, which state &#8216;The recommended dose is one Circadin tablet (2mg) taken daily by mouth after food, 12 hours before bedtime.&#8217; The instructions should state &#8216;The recommended dose is one Circadin tablet (2mg) taken daily by mouth after food, <span>1-2 hours before bedtime</span>.&#8217; The SPC is correct and an updated version of the PIL is presented on the Electronic Medicines Compendium. Health Care Professionals are asked to ensure that patients are made aware of the correct dosage instructions.</p>\n\n<p>In order to avoid stock disruption, affected stock is not being recalled. We understand that distribution of affected stock will cease as soon as stock containing the corrected PIL is available.</p>\n\n<p>Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter. Primary care trusts are asked to forward this to relevant clinics and to general practitioners and community pharmacists for information.</p>\n\n<p>Yours faithfully</p>\n\n<p>Alison Bunce<br>\nPharmaceutical Assessor, DMRC</p>\r\n\r\n\t\t\t\r\n        \t\t<!-- SS_END_SNIPPET(region1_element2,paged_publication)-->\r\n        \t\t\r\n        \t\tMHRA Distribution (further recipients by cascade):\r\n        \t\t\r\n        \t\t <!--SS_BEGIN_ELEMENT(region1_element18)-->\r\n        \t\tRegional Contacts for NHS Trusts and provider units<br>\nChief Pharmacists: England, Scotland, Wales, Northern Ireland<br>\nPrison Health Policy Unit (DH)<br>\nChief Pharmacists: &#160;Jersey, Guernsey, Alderney, Sark, Isle of Man, Gibraltar<br>\nSpecial Hospitals<br>\nHealthcare Commission for distribution to independent health care establishments<br>\nPrimary care trusts (England)\r\n        \t\t<!--SS_END_ELEMENT(region1_element18)-->\r\n \t\t\r\n\t\t\t\t<!-- SS_BEGIN_SNIPPET(region1_element3,static_pdf_list)-->\r\n        \t\t<!-- the xmlListTag variable is used by the searchDocsByContentIdList include to map the name of the XML node which contains the content id -->\r\n<!--perform the search -->\r\n\t\r\n\t<!-- <br>root: Content/AssociatedContent -->\r\n\t<!-- <br>ssFragmentInstanceId: region1_element3\t -->\r\n\t<!-- <br>SS_DATAFILE: CON251950 -->\r\n\t<!-- <br>xmlListTag: ContentId\t -->\r\n\t<!-- <br>XPATH: CON251950/Content/AssociatedContent/ContentId\t -->\r\n\r\n\t<!-- xmlListTag variable should be the name of the xml node which contains a contentid.  there should be a lis of these in the XML -->\r\n\t<!-- <br>strNumRecords: 1 -->\r\n\t<!-- <br>nNumRecords: 1 -->\r\n\r\n\t\t\t<!-- using the content ID above, get the docment from conetent server-->\r\n\r\n\t\t\t\r\n\r\n\t\t<!--  dDocName <matches>`CON251952` -->\r\n\t\t\r\n<div id=\"downloadArea\">\r\n\t<h3>Download documents:</h3>\r\n\t<ul>\r\n\t\t<!-- the SearchResults will have been initialised by the call to searchDocsByContentIdList above-->\r\n\t\t\t\r\n\t\t\t\t<li>\r\n\r\n\t\t\t\t\t\t<a href=\"#ASSET0\">ASSET_TAG</a>\r\n\t\t\t\t</li>\r\n\t</ul>\r\n\t<div class=\"clearing\"><!--  --></div>\r\n\t<!--<p><a class=\"doubleArrow\" target=\"new\" href=\"http://www.adobe.com/products/acrobat/readstep2.html\">Download Acrobat Reader for free</a></p>\r\n\t<p><a class=\"doubleArrow\" target=\"new\" href=\"http://www.adobe.com/products/acrobat/access_onlinetools.html\">Adobe text conversion tools</a></p>-->\r\n</div>\r\n\t\t\t\r\n        \t\t<!-- SS_END_SNIPPET(region1_element3,static_pdf_list)-->\r\n \t\t\r\n\t\t\t\t<!-- SS_BEGIN_CLOSEREGIONMARKER(region1)-->\r\n        \t\t\r\n        \t\t<!-- SS_END_CLOSEREGIONMARKER(region1)-->\r\n\t\t\t</div>\r\n\t\t", 
  "title": "Class 4 Drug Alert (Caution in Use): Circadin 2mg prolonged-release tablets - RAD Neurim Pharmaceuticals EEC Limited - EL (13)A/10", 
  "alert_type": [
    "drugs"
  ], 
  "medical_specialism": []
}